Disease · MONDO_0021553

transverse myelitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. transverse myelitis. Diseases, record MONDO_0021553. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021553

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: transverse myelitis; Open Targets
Open Targets ID: MONDO_0021553; Open Targets
Other names: transverse myelopathy syndrome; Open Targets
Disease Ontology: DOID:0080743; Disease Ontology
Highest stage of its drugs: Phase 3, for 9 of its 21 drugs, from ClinicalTrials.gov; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
DALFAMPRIDINE	CHEMBL284348	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets47

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1441	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 1/2	https://conductscience.org/library/genes/931	Drugs and targets
C5	Complement C5	1	Complement C5 inhibitor	Phase 1/2	https://conductscience.org/library/genes/727	Drugs and targets
KCNA1	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3736	Drugs and targets
KCNA10	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3744	Drugs and targets
KCNA2	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3737	Drugs and targets
KCNA3	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3738	Drugs and targets
KCNA4	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3739	Drugs and targets
KCNA5	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3741	Drugs and targets

1 to 10 of 47

See all 47 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02166346	Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)	Phase 2	24	2018-04-17	Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS	DALFAMPRIDINE	Its record names the disease	ClinicalTrials.gov
NCT00904826	An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica	Phase 1/2	14	2013-11-04	Neuromyelitis Optica, Devic's Disease	ECULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00787722	Hematopoietic Stem Cell Transplant in Devic's Disease	Phase 1/2	13	2020-02-28	Devic's Disease	CYCLOPHOSPHAMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01759602	C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation	Phase 1	10	2014-07-18	Neuromyelitis Optica	CONESTAT ALFA	Its record names the disease	ClinicalTrials.gov
NCT01777412	Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations	Phase 1	10	2015-05-29	Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02276963	Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses	Phase 1	6	2019-06-06	Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder	UBLITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03138421	Central Pain Study for ABX-1431	Phase 1	9		Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis	ELCUBRAGISTAT	Its record names the disease	ClinicalTrials.gov
NCT02398994	A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis	Phase 3	2		Myelitis, Transverse, Neuromyelitis Optica	METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dalfampridine vs Placebo: deaths from any cause	0 of 13	0 of 13	26	NCT02166346	Trial comparisons
Dalfampridine vs Placebo: serious adverse events	0 of 13	0 of 13	26	NCT02166346	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23623397	RESULT	1	PubMed
28639937	DERIVED	1	PubMed
26009577	DERIVED	1	PubMed
25191939	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021553

GET https://conductscience.org/api/diseases/v1/MONDO_0021553/drugs?page=2

API reference For AI assistants